Fennec Pharmaceuticals Inc. (FENC) Income Statement Analysis

See more : Deutsche Telekom AG (DTEA.DE) Income Statement Analysis – Financial Results

Complete financial analysis of Fennec Pharmaceuticals Inc. (FENC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Fennec Pharmaceuticals Inc., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

Maruhachi Securities Co., Ltd. (8700.T) Income Statement Analysis – Financial Results
Empower Clinics Inc. (EPW.CN) Income Statement Analysis – Financial Results
Zhejiang Jiaxin Silk Corp., Ltd. (002404.SZ) Income Statement Analysis – Financial Results
10X Capital Venture Acquisition Corp. II (VCXAW) Income Statement Analysis – Financial Results
Orbia Advance Corporation, S.A.B. de C.V. (ORBIA.MX) Income Statement Analysis – Financial Results

Fennec Pharmaceuticals Inc. (FENC)

Industry: Biotechnology

Sector: Healthcare

Website: https://www.fennecpharma.com

About Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000
Revenue	21.25M	1.54M	0.00	170.00K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.66	0.68
Cost of Revenue	1.26M	86.00K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-55.23K	0.00
Gross Profit	19.99M	1.45M	0.00	170.00K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	55.23K	0.68
Gross Profit Ratio	94.08%	94.40%	0.00%	100.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	8,359,700.00%	100.00%
Research & Development	56.00K	3.53M	4.98M	5.11M	5.61M	5.01M	1.94M	472.00K	256.00K	357.00K	597.00K	2.08M	1.49M	708.00K	2.11M	10.37M	10.91M	14.00M	12.44M	3.59M	3.55M	3.13M	1.91M	939.36K
General & Administrative	20.59M	17.72M	12.24M	12.95M	7.40M	5.40M	5.02M	2.40M	1.63M	2.52M	1.33M	1.55M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Selling & Marketing	12.12M	2.79M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	32.71M	20.51M	12.24M	12.95M	7.40M	5.40M	5.02M	2.40M	1.63M	2.52M	1.33M	1.55M	1.94M	3.90M	1.21M	3.52M	3.28M	2.88M	3.18M	3.49M	1.78M	907.40K	738.72K	614.25K
Other Expenses	0.00	0.00	0.00	-9.00K	-17.00K	6.00K	-8.00K	-14.00K	0.00	0.00	-3.00K	-5.00K	0.00	0.00	0.00	0.00	0.00	2.18M	2.72M	2.34M	1.42M	0.00	55.23K	52.01K
Operating Expenses	32.76M	24.04M	17.22M	18.06M	13.01M	10.41M	6.95M	2.87M	1.89M	2.88M	1.93M	3.62M	3.44M	4.60M	2.83M	13.89M	14.19M	19.06M	18.35M	9.42M	6.74M	4.04M	2.70M	1.61M
Cost & Expenses	34.06M	24.12M	17.22M	18.06M	13.01M	10.41M	6.95M	2.87M	1.89M	2.88M	1.93M	3.62M	3.44M	4.60M	2.83M	13.89M	14.19M	19.06M	18.35M	9.42M	6.74M	4.04M	2.65M	1.61M
Interest Income	441.00K	195.00K	54.00K	87.00K	322.32K	0.00	0.00	0.00	3.00K	2.00K	2.00K	25.00K	43.00K	32.00K	47.00K	286.00K	833.00K	0.00	361.00K	0.00	0.00	0.00	0.00	0.00
Interest Expense	3.39M	978.00K	126.00K	9.00K	0.00	0.00	0.00	0.00	0.00	2.00K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-3.00K	11.00K	-444.00K	0.00	0.00	0.00	0.00
Depreciation & Amortization	287.00K	149.00K	17.22M	402.00K	13.01M	10.41M	6.95M	2.87M	-1.23M	-699.00K	-1.00K	20.00K	43.00K	3.25M	615.00K	164.00K	192.00K	2.43M	3.06M	2.52M	1.61M	123.76K	55.23K	52.01K
EBITDA	-12.36M	-22.59M	-123.00K	-17.89M	234.00K	521.00K	-95.00K	82.00K	-1.89M	-2.88M	1.79M	-5.18M	4.55M	-4.60M	-2.60M	-13.89M	-14.19M	-17.91M	-19.27M	-12.56M	-5.22M	-4.24M	-2.79M	-2.59M
EBITDA Ratio	-58.18%	-1,468.60%	0.00%	-10,579.41%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-421,928,118.14%	-231,162,432.56%
Operating Income	-12.77M	-22.59M	-17.22M	-17.89M	-13.01M	-10.41M	-6.95M	-2.87M	-1.89M	-2.88M	-1.93M	-3.62M	-3.44M	-4.60M	-3.22M	-13.89M	-14.19M	-19.06M	-18.35M	-9.42M	-6.74M	-4.04M	-2.65M	-1.61M
Operating Income Ratio	-60.09%	-1,471.60%	0.00%	-10,520.59%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-400,900,112.25%	-237,629,943.17%
Total Other Income/Expenses	-3.27M	-1.13M	-123.00K	-224.00K	234.00K	521.00K	-95.00K	82.00K	1.28M	701.00K	3.78M	-1.54M	8.12M	-3.51M	204.00K	0.00	905.96K	-1.54M	-3.99M	-227.00K	79.44K	321.36K	194.17K	8.31K
Income Before Tax	-16.05M	-23.71M	-17.35M	-18.11M	-12.78M	-9.89M	-7.05M	-2.79M	-659.00K	-2.18M	1.85M	-5.16M	4.69M	-7.82M	-3.01M	-13.60M	-13.36M	-20.64M	-21.54M	-9.59M	-6.67M	-3.72M	-2.45M	-1.60M
Income Before Tax Ratio	-75.50%	-1,544.89%	0.00%	-10,652.35%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-371,512,604.02%	-236,400,367.04%
Income Tax Expense	0.00	1.13M	110.00K	-187.00K	-315.00K	-348.00K	-47.00K	-8.00K	-3.00K	-2.00K	-2.00K	-25.00K	-43.00K	7.82M	3.01M	13.60M	13.36M	-1.54M	-2.29M	-854.68K	-518.20K	3.72M	2.45M	1.60M
Net Income	-16.05M	-24.84M	-17.46M	-17.92M	-12.46M	-9.89M	-7.05M	-2.79M	-659.00K	-2.18M	1.85M	-5.16M	4.69M	-7.82M	-3.01M	-13.60M	-13.36M	-19.10M	-19.25M	-8.74M	-6.15M	-3.72M	-2.45M	-1.60M
Net Income Ratio	-75.50%	-1,618.18%	0.00%	-10,542.35%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-371,512,604.02%	-236,400,367.04%
EPS	-0.60	-0.95	-0.67	-0.76	-0.63	-0.52	-0.47	-0.22	-0.06	-0.22	0.19	-0.63	0.59	-1.11	-0.98	-4.43	-4.78	-16.72	-20.45	-15.04	-19.85	-19.32	-20.12	-2.98
EPS Diluted	-0.60	-0.95	-0.67	-0.76	-0.63	-0.52	-0.47	-0.22	-0.06	-0.22	0.17	-0.62	0.58	-1.11	-0.98	-4.43	-4.78	-16.72	-20.45	-15.04	-19.85	-19.32	-4.04	-2.98
Weighted Avg Shares Out	26.57M	26.28M	26.01M	23.70M	19.90M	18.94M	14.99M	12.68M	10.83M	9.87M	9.72M	8.20M	7.99M	7.08M	3.07M	3.07M	2.79M	1.14M	941.26K	580.75K	309.64K	192.51K	122.02K	536.64K
Weighted Avg Shares Out (Dil)	26.57M	26.28M	26.01M	23.70M	19.90M	19.02M	15.01M	12.77M	10.83M	9.87M	10.57M	8.39M	8.02M	7.08M	3.07M	3.07M	2.79M	1.14M	941.26K	580.75K	309.64K	192.51K	607.09K	536.64K

Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences

May 23, 2022globenewswire.com

RESEARCH TRIANGLE PARK, N.C., May 23, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate) for the prevention of platinum-induced ototoxicity in pediatric patients,...

FENC Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Fennec Pharmaceuticals Inc. Investors of Class Action and Last Few Hours to Contact the Firm

April 11, 2022businesswire.com

NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Fennec Pharmaceuticals Inc. ("Fennec" or the "Company") (NASDAQ: FENC) and certain of its officers, on behalf of shareholders who purchased or...

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Fennec Pharmaceuticals Inc. (FENC)

April 8, 2022businesswire.com

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming April 11, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Fennec Pharmaceuticals Inc. (“Fennec” or...

New Strong Sell Stocks for April 5th

April 5, 2022zacks.com

FENC, ALKT, and AMADY have been added to the Zacks Rank #5 (Strong Sell) List on April 5, 2022.

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Fennec Pharmaceuticals Inc. (FENC)

February 22, 2022businesswire.com

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming April 11, 2022 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Fennec Pharmaceuticals Inc. (“Fennec” or the “Company”)...

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Fennec Pharmaceuticals Inc. (FENC)

February 18, 2022businesswire.com

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming April 11, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Fennec Pharmaceuticals Inc....

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Fennec Pharmaceuticals Inc. (FENC) Investors

February 16, 2022businesswire.com

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Fennec Pharmaceuticals Inc. (“Fennec” or the “Company”) (NASDAQ: FENC) securities between May 28, 2021 and November 26,...

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Fennec Pharmaceuticals Inc. (FENC) Investors

February 15, 2022businesswire.com

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Fennec Pharmaceuticals Inc. (“Fennec” or the “Company”)...

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Fennec Pharmaceuticals Inc. (FENC) Investors

February 14, 2022businesswire.com

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Fennec Pharmaceuticals Inc. (“Fennec” or the “Company”) (NASDAQ: FENC) securities between...